Pharmacogenetics: Ethical issues and policy options

Allen Buchanan; Andrea Califano; Jeffrey Kahn; Elizabeth McPherson; John Robertson; Baruch Brody

doi:10.4324/9781315254517-12

Pharmacogenetics: Ethical issues and policy options

Allen Buchanan, Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John Robertson, Baruch Brody

Philosophy

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Pharmacogenetics offers the prospect of an era of safer and more effective drugs, as well as more individualized use of drug therapies. Before the benefits of pharmacogenetics can be realized, the ethical issues that arise in research and clinical application of pharmacogenetic technologies must be addressed. The ethical issues raised by pharmacogenetics can be addressed under six headings: (1) regulatory oversight, (2) confidentiality and privacy, (3) informed consent, (4) availability of drugs, (5) access, and (6) clinicians’ changing responsibilities in the era of pharmacogenetic medicine. We analyze each of these categories of ethical issues and provide policy approaches for addressing them.

Original language	English (US)
Title of host publication	Genetics and Gene Therapy
Publisher	Taylor and Francis
Pages	327-341
Number of pages	15
ISBN (Electronic)	9781351934282
ISBN (Print)	9780754620556
DOIs	https://doi.org/10.4324/9781315254517-12
State	Published - Jan 1 2017

ASJC Scopus subject areas

General Medicine
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.4324/9781315254517-12

Cite this

@inbook{2a38f0e6b78d45f28e1c2e2a03fcb833,

title = "Pharmacogenetics: Ethical issues and policy options",

abstract = "Pharmacogenetics offers the prospect of an era of safer and more effective drugs, as well as more individualized use of drug therapies. Before the benefits of pharmacogenetics can be realized, the ethical issues that arise in research and clinical application of pharmacogenetic technologies must be addressed. The ethical issues raised by pharmacogenetics can be addressed under six headings: (1) regulatory oversight, (2) confidentiality and privacy, (3) informed consent, (4) availability of drugs, (5) access, and (6) clinicians{\textquoteright} changing responsibilities in the era of pharmacogenetic medicine. We analyze each of these categories of ethical issues and provide policy approaches for addressing them.",

author = "Allen Buchanan and Andrea Califano and Jeffrey Kahn and Elizabeth McPherson and John Robertson and Baruch Brody",

note = "Publisher Copyright: {\textcopyright} Sheila A.M. McLean 2005.",

year = "2017",

month = jan,

day = "1",

doi = "10.4324/9781315254517-12",

language = "English (US)",

isbn = "9780754620556",

pages = "327--341",

booktitle = "Genetics and Gene Therapy",

publisher = "Taylor and Francis",

}

TY - CHAP

T1 - Pharmacogenetics

T2 - Ethical issues and policy options

AU - Buchanan, Allen

AU - Califano, Andrea

AU - Kahn, Jeffrey

AU - McPherson, Elizabeth

AU - Robertson, John

AU - Brody, Baruch

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Pharmacogenetics offers the prospect of an era of safer and more effective drugs, as well as more individualized use of drug therapies. Before the benefits of pharmacogenetics can be realized, the ethical issues that arise in research and clinical application of pharmacogenetic technologies must be addressed. The ethical issues raised by pharmacogenetics can be addressed under six headings: (1) regulatory oversight, (2) confidentiality and privacy, (3) informed consent, (4) availability of drugs, (5) access, and (6) clinicians’ changing responsibilities in the era of pharmacogenetic medicine. We analyze each of these categories of ethical issues and provide policy approaches for addressing them.

AB - Pharmacogenetics offers the prospect of an era of safer and more effective drugs, as well as more individualized use of drug therapies. Before the benefits of pharmacogenetics can be realized, the ethical issues that arise in research and clinical application of pharmacogenetic technologies must be addressed. The ethical issues raised by pharmacogenetics can be addressed under six headings: (1) regulatory oversight, (2) confidentiality and privacy, (3) informed consent, (4) availability of drugs, (5) access, and (6) clinicians’ changing responsibilities in the era of pharmacogenetic medicine. We analyze each of these categories of ethical issues and provide policy approaches for addressing them.

UR - http://www.scopus.com/inward/record.url?scp=85084885191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084885191&partnerID=8YFLogxK

U2 - 10.4324/9781315254517-12

DO - 10.4324/9781315254517-12

M3 - Chapter

AN - SCOPUS:85084885191

SN - 9780754620556

SP - 327

EP - 341

BT - Genetics and Gene Therapy

PB - Taylor and Francis

ER -

Pharmacogenetics: Ethical issues and policy options

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this